The Enigmatic Helicase DHX9 and Its Association With the Hallmarks of Cancer

Gulliver, Chloe; Hoffmann, Ralf; Baillie, George S.

doi:10.2144/fsoa-2020-0140

Cited by 28 publications

(26 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 59 The involvement of DHX9 in malignancies makes it an attractive biomarker and target for cancer therapy. 60 In our research, DHX9 was overexpressed in stage II in B cells of the CRC-adjacent tissue ( Figure 5 B). DHX9 and its related genes such as STRAP, CHO4 , and SNRPB2 exhibited a synergistic change at the network level ( Figure S8 ).…”

Section: Discussionsupporting

confidence: 51%

Single-cell transcriptomics reveal DHX9 in mature B cell as a dynamic network biomarker before lymph node metastasis in CRC

Liu

Zhong

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Increasing evidence indicates that mature B cells in the adjacent tumor tissue, both as an intermediate state, are vital in advanced colorectal cancer (CRC), which is associated with a low survival rate. Developing predictive biomarkers that detect the tipping point of mature B cells before lymph node metastasis in CRC is critical to prevent irreversible deterioration. We analyzed B cells in the adjacent tissues of CRC samples from different stages using the dynamic network biomarker (DNB) method. Single-cell profiling of 725 CRC-derived B cells revealed the emergence of a mature B cell subtype. Using the DNB method, we identified stage II as a critical period before lymph node metastasis and that reversed difference genes triggered by DNBs were enriched in the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway involving B cell immune capability. DHX9 (DEAH-box helicase 9) was a specific para-cancerous tissue DNB key gene. The dynamic expression levels of DHX9 and its proximate network genes involved in B cell-related pathways were reversed at the network level from stage I to III. In summary, DHX9 in mature B cells of CRC-adjacent tissues may serve as a predictable biomarker and a potential immune target in CRC progression.

show abstract

Section: Discussionsupporting

confidence: 51%

Single-cell transcriptomics reveal DHX9 in mature B cell as a dynamic network biomarker before lymph node metastasis in CRC

Liu

Zhong

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

show abstract

“… 6 Much effort has been expended lately in characterizing the association between DHX9 dysregulation and cancer development; however, there is still conflict as to whether it regularly functions as an oncogene or tumor suppressor. 11 The effect of DHX9 on cancers appears to be cell‐type specific, dependent on the kind of binding partners. 11 , 12 Some studies suggested that DHX9 functioned as an oncogene and highly expressed in cancer tissues.…”

Section: Discussionmentioning

confidence: 99%

“… 11 The effect of DHX9 on cancers appears to be cell‐type specific, dependent on the kind of binding partners. 11 , 12 Some studies suggested that DHX9 functioned as an oncogene and highly expressed in cancer tissues. 13 Palombo et al 14 showed that poison‐exon inclusion in DHX9 by hnRNPM and SRSF3 reduced its expression and inhibited cell proliferation in Ewing sarcoma malignancy.…”

Section: Discussionmentioning

confidence: 99%

High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma

Shi

Cao

Zhu

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Liver cancer is one of the most common malignant tumors worldwide, and it ranks sixth in terms of global incidence and third in terms of mortality in 2020, with approximately 906,000 new cases and 830,000 deaths. 1,2 Hepatocellular carcinoma (HCC) is the most common type of liver cancer (comprising 75%-85% of cases). 1 In recent years, despite the continuous improvements in the efficacy of surgical treatment and adjuvant chemotherapy, the overall 5-year survival rate of patients with liver cancer remains between 30% and 40%. 3 The occurrence of HCC is a complex multi-step process that involves the imbalance of cell signal transduction pathways, the deletion of DNA repair regulatory gene, the activation of proto-oncogenes, and the inactivation of

show abstract

“…Additionally, it was also shown to modulate circulatory RNAs during EMT. (238). Ring1b, a core component of the Polycomb Repressive Complex 1 (PRC1) has been shown to form complex with DEAD-box RNA helicases such as DDX3X and DDX5 and downregulate E-cadherin by binding to its promoter.…”

Section: Elk3 Has Been Shown To Positively Influence Emt In Breast Cancer Cells As Well As During Progressionmentioning

confidence: 99%

Epithelial–mesenchymal transition and its transcription factors

et al. 2021

View full text Add to dashboard Cite

Epithelial-mesenchymal transition or EMT is an extremely dynamic process involved in conversion of epithelial cells into mesenchymal cells, stimulated by an ensemble of signaling pathways, leading to change in cellular morphology, suppression of epithelial characters and acquisition of properties such as enhanced cell motility and invasiveness, reduced cell death by apoptosis, resistance to chemotherapeutic drugs etc. Significantly, EMT has been found to play a crucial role during embryonic development, tissue fibrosis and would healing, as well as during cancer metastasis. Over the years, work from various laboratories have identified a rather large number of transcription factors including the master regulators of EMT, with the ability to regulate the EMT process directly. In this review, we put together these EMT transcription factors and discussed their role in the process. We have also tried to focus on their mechanism of action, their inter-dependency, and the large regulatory network they form. Subsequently, it has become clear that the composition and structure of the transcriptional regulatory network behind EMT probably varies based upon various physiological and pathological contexts, or even in a cell/tissue type dependent manner.

show abstract

The Enigmatic Helicase DHX9 and Its Association With the Hallmarks of Cancer

Cited by 28 publications

References 119 publications

Single-cell transcriptomics reveal DHX9 in mature B cell as a dynamic network biomarker before lymph node metastasis in CRC

Single-cell transcriptomics reveal DHX9 in mature B cell as a dynamic network biomarker before lymph node metastasis in CRC

High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma

Epithelial–mesenchymal transition and its transcription factors

Contact Info

Product

Resources

About